Table 1. Clinicopathological treatment, outcome and EDD expression data for the serous ovarian cancer patient cohort (n=151)a.
| Variable | n (%) |
|---|---|
| EDD expression | |
| Low/absent (<6) | 64 (42.4) |
| High (⩾6) | 87 (57.6) |
| Age (years) | |
| >60 | 71 (47.0) |
| ⩽60 | 80 (53.0) |
| FIGO Stage | |
| I, II | 16 (10.6) |
| III, IV | 135 (89.4) |
| Tumour grade | |
| 1 | 7 (4.6) |
| 2, 3 | 144 (95.4) |
| Surgical debulking | |
| Optimal ⩽1 cm | 89 (58.9) |
| Suboptimal >1 cm | 62 (41.1) |
| Menopausal status (n=150) | |
| Pre/peri | 34 (22.7) |
| Post | 116 (77.3) |
| CA125 (n=128) | |
| ⩽500 | 54 (42.2) |
| >500 | 74 (57.8) |
| Adjuvant chemotherapy (n=145) | |
| P only | 19 (13.1) |
| P+C | 76 (52.5) |
| P+T | 44 (30.3) |
| M only | 6 (4.1) |
| Outcome | |
| Complete response to treatment | 114 (75.5) |
| Progressive disease | 37 (24.5) |
| Recurrenceb | 96 (84.2) |
| Death | 123 (81.4) |
C=cyclophosphamide; M=melphalan; P=platinum; T=paclitaxel.
a
n=151 unless otherwise stated.
b
In patients with complete response to treatment (n=114).